Document is current
Any future updates will be listed below
-
Authors
Erritzoe, David https://orcid.org/0000-0002-7022-6211
Barba, Tommaso https://orcid.org/0000-0003-2565-4628
Benway, Tiffanie
Joel, Zelah
Good, Meghan
Layzell, Marie
Jones, Michelle Baker https://orcid.org/0009-0004-6557-0503
Campbell, Graham
Murphy-Beiner, Ashleigh
Rands, Peter
Boyce, Malcolm
Topping, Helen
Weiss, Brandon
Timmermann, Christopher https://orcid.org/0000-0002-2281-377X
Nutt, David https://orcid.org/0000-0002-1286-1401
Carhart-Harris, Robin https://orcid.org/0000-0002-6062-7150
Routledge, Carol
James, Ellen https://orcid.org/0009-0000-9554-573X
-
Funding
Funding for this research was provided by:
Trial sponsored by Small Pharma LTD
- License Information
-
More Information
Article History
Received: 5 June 2025
Accepted: 2 December 2025
First Online: 16 February 2026
Competing interests
: D.E. serves as a paid scientific advisor for Aya Biosciences, Lophora Aps, Clerkenwell Health and Mindstate Design Lab. D.N. has no current affiliations with companies developing psychedelic treatments for depression, although he previously advised COMPASS Pathways. He currently advises Algernon Pharmaceuticals on the nonpsychedelic application of DMT for stroke and Neural Therapeutics on mescaline research. G.C. was employed by Small Pharma at the time of the trial (fully seconded to HMR). C.R. and P.R. were employed by Small Pharma and held shares in the company at the time of the trial. R.C.-H. is a scientific advisor to TRYP Therapeutics, MindState and Otsuka. T. Benway was employed by Small Pharma during the trial and is a shareholder; she is now employed by GH Research. E.J., M.L., Z.J. and M.G. were employed by Small Pharma and are now employed by Cybin UK/IRL, trading as Helus/CybinIRL, and are option holders/shareholders in Cybin. The other authors declare no competing interests.
